STENTYS Enrolls First 250 Patients, Half Of Apposition III Study Of Its Self-Apposing Stent For Treatment Of Heart Attacks
Links shared publicly online about this topic.
- 322total visits
STENTYS Enrolls First 250 Patients, Half Of Apposition III Study Of Its Self-Apposing Stent For Treatment Of Heart Attacks
STENTYS S.A. (STNT.PA), a medical technology company that is commercializing a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has reached t
View full resource at medicalnewstoday.com
Tags: Heart, Heart Disease, Heart Attack, Thrombotic Event, Medical, Medical Technology
Most Recently Shared on May 2, 2011 at 6:32 pm By:
STENTYS Enrolls First 250 Patients, Half Of Apposition III Study Of Its Self-Apposing Stent For Treat... http://bit.ly/mMRO81 #MedDevice
STENTYS Enrolls First 250 Patients, Half Of Apposition III Study Of Its Self-Apposing Stent For Treatment Of Heart Attacks
medicalnewstoday.com — “STENTYS S.A. (STNT.PA), a medical technology company that is commercializing a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has reached t” View full resource at medicalnewstoday.com
Most Recently Shared on May 2, 2011 at 3:05 pm By:
MNT Medical Devices Health News
STENTYS Enrolls First 250 Patients, Half Of Apposition III Study Of Its Self-Apposing Stent For Treatment Of Heart Att... http://mnt.to/3Vgp
Advertisement
